万泰生物：上半年净利润亏损1.44亿元 同比转亏

Group 1 - The company WanTai Bio (603392.SH) reported a revenue of 844 million yuan for the first half of 2025, representing a year-on-year decline of 38.25% [1] - The net profit attributable to shareholders of the listed company was a loss of 144 million yuan, indicating a shift from profit to loss compared to the previous year [1] - The decline in revenue is primarily attributed to market competition affecting the sales of the bivalent cervical cancer vaccine, which did not meet expectations [1]